Rubicon Research Ltd
Company Profile
Business description
Rubicon Research Ltd is a pharmaceutical company focusing on developing and manufacturing specialty and generic pharmaceutical products. Its portfolio spans multiple dosage forms, including oral solids, liquids, nasal, ophthalmic, injectable, topical, drug-device combinations, and fixed-dose combinations. The company leverages proprietary drug delivery technologies, like RubiSRL and RubiReten, and formulation expertise to address complex development challenges. It operates manufacturing and R&D facilities in India, Canada, and the United States. Rubicon generates revenue by supplying these diverse pharmaceutical products to regulated markets globally. Subsidiaries support product development, personal wellness offerings in India, and pharmaceutical training through a learning platform.
Contact
Road No. 33
MedOne House, B-75
Wagle Estate
Thane WestMH400 604
INDT: +91 2261414000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 March 2026
Employees
1,141
Stocks News & Analysis
stocks
New production imminent for undervalued ASX gas play
stocks
Going into earnings, is Tesla stock a buy, a sell, or fairly valued?
stocks
Why I dislike dividend stocks
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,293.20 | 45.10 | -0.48% |
| CAC 40 | 8,189.52 | 0.93 | 0.01% |
| DAX 40 | 23,830.99 | 441.20 | -1.82% |
| Dow JONES (US) | 46,190.61 | 238.37 | 0.52% |
| FTSE 100 | 9,348.01 | 88.08 | -0.93% |
| HKSE | 25,247.10 | 641.41 | -2.48% |
| NASDAQ | 22,679.97 | 117.44 | 0.52% |
| Nikkei 225 | 47,582.15 | 695.59 | -1.44% |
| NZX 50 Index | 13,279.53 | 9.68 | -0.07% |
| S&P 500 | 6,664.01 | 34.94 | 0.53% |
| S&P/ASX 200 | 8,995.30 | 34.70 | -0.38% |
| SSE Composite Index | 3,839.76 | 76.47 | -1.95% |